Top Markets
#1 Helium Helium +93.49%
#2 MowCat MowCat +84.25%
#3 Seeker Seeker +49.37%
#4 UnifAI Network UnifAI Network +32.18%
#5 TENDIES TENDIES +30.27%
#6 Pons Pons +24.00%
#7 Zylo Ecosystem Zylo Ecosystem +22.28%
#8 Bounce Bounce +18.04%
#9 Tensor Tensor +17.67%
#10 Zora Zora +16.77%
Coin of the day
Helium Helium
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Sangamo Therapeutics, Inc. Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc.

GBY
Classificação em ações #11086
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic medicines designed to significantly improve patients' lives. The company employs cutting-edge platform technologies, including gene therapy, cell therapy, genome editing, and genome regulation. Central to their technological approach is the zinc finger protein (ZFP) platform, which provides both ZFP nucleases for precise DNA sequence modification (allowing for gene addition or knockout) and ZFP transcription factors for upregulating or downregulating gene expression. Their development pipeline includes SB-525, currently in a Phase III AFFINE clinical trial for hemophilia A; ST-920, a gene therapy in Phase I/II STAAR trials for Fabry disease; and SAR445136, a cell therapy undergoing Phase I/II PRECIZN-1 trials for sickle cell disease. Additionally, Sangamo is advancing TX200, a chimeric antigen receptor for HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy targeting cancer; ST-501 for tauopathies; and ST-502 for synucleinopathies, which include Parkinson's disease and other neuromuscular disorders. The company maintains extensive collaborative and strategic partnerships with prominent organizations such as Biogen MA, Inc., Pfizer Inc., Sanofi S.A., Novartis Institutes for BioMedical Research, Inc., and F. Hoffmann-La Roche Ltd. Originally incorporated in 1995 as Sangamo BioSciences, Inc., the company adopted its current name in January 2017 and is headquartered in Brisbane, California.
Preço da ação
$5.21
Última sincronização: 2022-08-11
Valor de mercado
$745.49M
Variação (1 dia)
0.15%
Variação (1 ano)
0.00%
País
US
Negociar Sangamo Therapeutics, Inc. (GBY)

Categoria

Healthcare
Rácio P/B de Sangamo Therapeutics, Inc. (GBY)
Rácio P/B em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da Sangamo Therapeutics, Inc., o rácio P/B atual (TTM) é 0. No final de 2026, o rácio P/B era 0.
Histórico do rácio P/B da Sangamo Therapeutics, Inc. de 2026 a 2026
Rácio P/B no final de cada ano
Ano Rácio P/B Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/B de empresas semelhantes ou concorrentes
Empresa Rácio P/B Diferença do rácio P/B País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH